⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29237016 | 0.85 | — | — | |
| SCHEMBL31607155 | 0.85 | — | — | |
| SCHEMBL16036675 | 0.81 | — | — | |
| SCHEMBL28395090 | 0.81 | — | — | |
| SCHEMBL31015135 | 0.81 | — | — | |
| SCHEMBL15956513 | 0.81 | — | — | |
| SCHEMBL25120101 | 0.75 | KDM4E (0.34) | — | |
| SCHEMBL28389028 | 0.75 | SMN1; SMN2 (0.36) | — | |
| SCHEMBL25120102 | 0.75 | LOX (0.32) | — | |
| SCHEMBL30616000 | 0.75 | ADORA2A (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036769-A | Condensed ring organic compound containing boron-nitrogen heteroatom and electroluminescent device | 西安欧得光电材料有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260116868-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4731207-A2 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | Merck Sharp & Dohme LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4727922-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4720040-A1 | SULFONAMIDE COMPOUNDS BENEFICIAL IN NEUROPROTECTIVE TREATMENT | Lario Therapeutics Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-12595239-B2 | Substituted isoxazoline derivatives | BASF SE (DE) | 2026-04-07 | — | — | US | disclosed |
| US-12565494-B2 | Inhibitors of human respiratory syncytial virus and metapneumovirus | MERCK SHARP & DOHME LLC | 2026-03-03 | — | — | US | disclosed |
| EP-4313981-B1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | PFIZER (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-4695259-A1 | TRICYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-4688790-A1 | MACROCYCLIC RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| WO-2006078992-A2 | HETEROARYL SUBSTITUTED PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060122394-A1 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2006-06-08 | — | — | US | disclosed |
| EP-1644358-A2 | BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2006026135-A2 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-03-09 | — | — | WO | disclosed |
| WO-2005007648-A2 | BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| US-4529447-A | Containing an acid anhydride and emulsifier | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 1985-07-16 | — | — | US | disclosed |
| US-4521603-A | Continuous process for the production of polybromopyridine compounds | OLIN CORPORATION (US) | 1985-06-04 | — | — | US | disclosed |